HUE062729T2 - Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra - Google Patents
Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásraInfo
- Publication number
- HUE062729T2 HUE062729T2 HUE18715909A HUE18715909A HUE062729T2 HU E062729 T2 HUE062729 T2 HU E062729T2 HU E18715909 A HUE18715909 A HU E18715909A HU E18715909 A HUE18715909 A HU E18715909A HU E062729 T2 HUE062729 T2 HU E062729T2
- Authority
- HU
- Hungary
- Prior art keywords
- betahistine
- vertigo
- symptoms
- prevention
- subject
- Prior art date
Links
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 title 1
- 208000012886 Vertigo Diseases 0.000 title 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 title 1
- 229960004536 betahistine Drugs 0.000 title 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 231100000889 vertigo Toxicity 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1704949.5A GB201704949D0 (en) | 2017-03-28 | 2017-03-28 | Combination treatment |
| GBGB1711677.3A GB201711677D0 (en) | 2017-07-20 | 2017-07-20 | Combination treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE062729T2 true HUE062729T2 (hu) | 2023-12-28 |
Family
ID=61906770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18715909A HUE062729T2 (hu) | 2017-03-28 | 2018-03-28 | Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11083718B2 (hu) |
| EP (2) | EP3600276B1 (hu) |
| DK (1) | DK3600276T3 (hu) |
| ES (1) | ES2950452T3 (hu) |
| FI (1) | FI3600276T3 (hu) |
| HR (1) | HRP20230735T1 (hu) |
| HU (1) | HUE062729T2 (hu) |
| LT (1) | LT3600276T (hu) |
| PL (1) | PL3600276T3 (hu) |
| PT (1) | PT3600276T (hu) |
| RS (1) | RS64304B1 (hu) |
| SI (1) | SI3600276T1 (hu) |
| WO (1) | WO2018178670A1 (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64304B1 (sr) | 2017-03-28 | 2023-07-31 | Intrabio Ltd | Betahistin, ili njegova farmaceutski prihvatljiva so, i inhibitor monoaminske oksidaze, za upotrebu u lečenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7728015B2 (en) | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| AU2009253739B2 (en) | 2008-05-27 | 2014-02-06 | Otolanum Ag | Methods of treating mammals with eustachian tube dysfunctions |
| EP2491930A1 (en) | 2011-02-25 | 2012-08-29 | Deva Holding Anonim Sirketi | Pharmaceutical combination of betahistine and trimetazidine |
| RS64304B1 (sr) * | 2017-03-28 | 2023-07-31 | Intrabio Ltd | Betahistin, ili njegova farmaceutski prihvatljiva so, i inhibitor monoaminske oksidaze, za upotrebu u lečenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta |
-
2018
- 2018-03-28 RS RS20230485A patent/RS64304B1/sr unknown
- 2018-03-28 EP EP18715909.0A patent/EP3600276B1/en active Active
- 2018-03-28 SI SI201830944T patent/SI3600276T1/sl unknown
- 2018-03-28 US US16/499,087 patent/US11083718B2/en active Active
- 2018-03-28 HU HUE18715909A patent/HUE062729T2/hu unknown
- 2018-03-28 PT PT187159090T patent/PT3600276T/pt unknown
- 2018-03-28 HR HRP20230735TT patent/HRP20230735T1/hr unknown
- 2018-03-28 WO PCT/GB2018/050822 patent/WO2018178670A1/en unknown
- 2018-03-28 FI FIEP18715909.0T patent/FI3600276T3/fi active
- 2018-03-28 DK DK18715909.0T patent/DK3600276T3/da active
- 2018-03-28 PL PL18715909.0T patent/PL3600276T3/pl unknown
- 2018-03-28 EP EP23176227.9A patent/EP4234022A3/en active Pending
- 2018-03-28 ES ES18715909T patent/ES2950452T3/es active Active
- 2018-03-28 LT LTEPPCT/GB2018/050822T patent/LT3600276T/lt unknown
-
2021
- 2021-08-06 US US17/396,064 patent/US11690830B2/en active Active
-
2023
- 2023-05-19 US US18/320,761 patent/US20230285373A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT3600276T (pt) | 2023-07-11 |
| RS64304B1 (sr) | 2023-07-31 |
| DK3600276T3 (da) | 2023-07-10 |
| US20210085659A1 (en) | 2021-03-25 |
| LT3600276T (lt) | 2023-08-10 |
| EP3600276A1 (en) | 2020-02-05 |
| US20210361632A1 (en) | 2021-11-25 |
| EP3600276B1 (en) | 2023-05-31 |
| HRP20230735T1 (hr) | 2023-10-13 |
| PL3600276T3 (pl) | 2023-08-21 |
| SI3600276T1 (sl) | 2023-08-31 |
| EP4234022A2 (en) | 2023-08-30 |
| WO2018178670A1 (en) | 2018-10-04 |
| US11083718B2 (en) | 2021-08-10 |
| US11690830B2 (en) | 2023-07-04 |
| ES2950452T3 (es) | 2023-10-10 |
| US20230285373A1 (en) | 2023-09-14 |
| FI3600276T3 (fi) | 2023-06-29 |
| EP4234022A3 (en) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288231A (en) | An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts. | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| IL282487A (en) | TYK2 inhibitors and their use | |
| SG11202013231SA (en) | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF | |
| IL268327A (en) | A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| IL282090A (en) | tyk2 inhibitors and uses thereof | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| MX2021010886A (es) | Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson. | |
| IL271728A (en) | Materials, uses and treatment methods | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| EP3541185A4 (en) | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | |
| IL273922A (en) | D-amino acid oxidase inhibitors and their therapeutic uses | |
| SI3600276T1 (sl) | Betahistin ali njegova farmacevtsko sprejemljiva sol in inhibitor monoaminoksidaze, za uporabo pri zdravljenju ali preprečevanju enega ali več simptomov vrtoglavice pri subjektu | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| NZ733451A (en) | Combination therapy for pulmonary hypertension | |
| WO2016126572A3 (en) | Glucosylceramide synthase inhibitors and therapeutic methods using the same | |
| GB201519258D0 (en) | Newly identified wnt/beta-catenin signal transduction inhibitors and the use thereof in the treatment or prevention of diseases and conditions. | |
| HK1246205A1 (zh) | 在預防和/或治療皮膚損傷中使用的至少一種蛋白酶抑制劑和至少一種活性成分的組合 | |
| NZ747201A (en) | (+)-azasetron for use in the treatment of ear disorders | |
| IL247616B (en) | Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit | |
| PT3319950T (pt) | Diaminas primárias vicinais associadas com motivos quelantes de metais e/ou de radicais livres, e ativas contra o stress carbonilo e oxidativo, e seu uso | |
| IL290328A (en) | Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate cancer | |
| PH12018500221A1 (en) | A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps) | |
| GEP20197038B (en) | Combination of at least one protease inhibitor and at least one active principle for use in the prevention and/or treatment of skin lesions |